CHSU Discovery

Abstract

Warfarin: oral anticoagulant used to prevent and treat thromboembolisms
• Mechanism of action: inhibits vitamin K epoxidase reductase, depletes vitamin K
stores, and reduces the synthesis of factors II, VII, IX, X, and Proteins C/S
• Management of warfarin associated coagulopathies: co-administration of fourfactor
prothrombin complex concentrates (4F-PCC) and vitamin K
• 4F-PCC: contains clotting factors II, VII, IX, X, and Proteins C/S; provides
immediate/temporary restoration of hemostasis
• Vitamin K: repletes vitamin K stores; provides delayed/sustained restoration
of hemostasis
• 4F-PCC dosing: standard or fixed-dose (Table 1)
• Fixed-dose regimens reduce drug costs, administration times, and
thromboembolic events
• Optimal fixed-dose regimen is unknown
• Community Medical Centers’ previous fixed-dose FEIBA regimen resulted in
55.6% of the population achieving a post-FEIBA administration INR of ≤ 1.5
• Findings resulted in a dose increase (Table 3)
• Study Purpose: determine if Community Medical Centers’ new fixed-dose FEIBA
regimen resulted in more patients achieving a post-FEIBA administration INR of
≤ 1.5